
|Videos|April 10, 2014
Custirsen as Treatment for Prostate Cancer
Author(s)Oliver Sartor, MD
Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses a phase III trial of custirsen (OGX-011) and its potential for treatment in patients with prostate cancer.
Advertisement
Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses a phase III trial of custirsen (OGX-011) and its potential for treatment in patients with prostate cancer.
Clinical Pearls:
- A phase III trial of custirsen in combination with docetaxel has been conducted and results are expected to be available within a year
- Based on a phase II trial, the combination appeared to be more effective than docetaxel when used as mono therapy
- This phase III trial will determine if custirsen plus docetaxel is more effective than docetaxel alone for patients with castration-resistant prostate cancer
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5










































